$2,608.44 consulting Payment -- Amgen Inc to Dr. Matthew Walker

Hematologist Matthew Walker Receives $2,608 Consulting Fee from Amgen for Trulicity

This page provides a detailed analysis of a $2,608.44 consulting payment from Amgen Inc to Dr. Matthew Walker. Data is from the CMS Open Payments (Sunshine Act) database.

Payment Details

FieldValue
Amount$2,608.44
Payment Typeconsulting
Payment NatureConsulting Fee
Pharmaceutical CompanyAmgen Inc
PhysicianDr. Matthew Walker
NPI Number1962961908
Physician SpecialtyHematology
LocationCity, MD
Date of Payment2025-03-28
Related Drug/DeviceTrulicity
Conflict AssessmentLow -- Routine

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Amgen Inc made a $2.6K consulting payment to Matthew Walker, a Hematology specialist in City, MD. The payment was associated with Trulicity. Matthew Walker received a $2,608.44 consulting fee from Amgen Inc. The payment was related to Trulicity, a drug used in Hematology. This payment occurred on March 28, 2025.

Patient Guidance: What This Payment Means for You

This information details a payment made to a healthcare provider for consulting services, which may inform discussions about their treatment recommendations. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Consulting fees for hematologists can vary widely depending on the scope of work and the pharmaceutical company's needs.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the Physician Payments Sunshine Act, part of the Affordable Care Act, which requires disclosure of financial relationships between drug and device manufacturers and physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

Understanding consulting Payments

Consulting payments are made when pharmaceutical companies hire physicians as advisors or consultants. This can include serving on advisory boards, providing expert medical opinions on drug development or marketing strategies, and reviewing clinical data. Consulting is one of the most common forms of pharmaceutical payment to physicians and can range from a few hundred dollars for a brief consultation to tens of thousands of dollars for ongoing advisory relationships.

Frequently Asked Questions About This Payment

What was this $2.6K payment for?

This was a consulting payment of $2.6K from Amgen Inc to Matthew Walker, categorized as "Consulting Fee". It was associated with Trulicity. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Matthew Walker accept pharmaceutical money?

Yes, Matthew Walker received this $2.6K payment from Amgen Inc. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Matthew Walker's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this consulting payment?

A consulting payment of $2.6K may reflect legitimate advisory services the physician provides. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Hematology?

To compare this payment against Hematology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hematology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Matthew Walker's relationship with Amgen Inc?

The payment was specifically for 'Consulting Fee' under the 'consulting' payment type. This $2.6K consulting payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Hematology?

The payment ID is OP-MNLJE9A9-QRQSFI.

What should patients do after learning about this payment?

This information details a payment made to a healthcare provider for consulting services, which may inform discussions about their treatment recommendations.

What else should I know about this consulting payment?

The payment was made by Amgen Inc.

Related Reports

Data from CMS Open Payments. Payment does not imply wrongdoing. Consult your healthcare provider about any concerns.